RRx-001

surprisingly well-tolerated clinical molecule

Ph. III candidate in SCLC (4 mg IV QW)

from aerospace compound phenotypic screen

J. Med. Chem., May 27, 2021

EpicentRx Inc., La Jolla, CA

The EpiCentRx Myc and CD47 downregulating molecule with a range of proposed mechanisms, RRx-001, is a Ph. III clinical candidate with an eyebrow-raising chemical structure that originated from an even…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.